Search

Your search keyword '"Li Gobbi, Francesca"' showing total 136 results
Start Over Author "Li Gobbi, Francesca"
136 results on '"Li Gobbi, Francesca"'

1. Development and implementation of the AIDA International Registry for patients with Behçet’s disease

Author

Vitale, Antonio, Della Casa, Francesca, Ragab, Gaafar, Almaghlouth, Ibrahim A., Lopalco, Giuseppe, Pereira, Rosa Maria, Guerriero, Silvana, Govoni, Marcello, Sfikakis, Petros P., Giacomelli, Roberto, Ciccia, Francesco, Monti, Sara, Ruscitti, Piero, Piga, Matteo, Lomater, Claudia, Tufan, Abdurrahman, Opris-Belinski, Daniela, Emmi, Giacomo, Hernández-Rodríguez, José, Şahin, Ali, Sebastiani, Gian Domenico, Bartoloni, Elena, Akkoç, Nurullah, Gündüz, Özgül Soysal, Cattalini, Marco, Conti, Giovanni, Hatemi, Gulen, Maier, Armin, Parronchi, Paola, Del Giudice, Emanuela, Erten, Sukran, Insalaco, Antonella, Li Gobbi, Francesca, Maggio, Maria Cristina, Shahram, Farhad, Caggiano, Valeria, Hegazy, Mohamed Tharwat, Asfina, Kazi Nur, Morrone, Maria, Prado, Leandro L., Dammacco, Rosanna, Ruffilli, Francesca, Arida, Aikaterini, Navarini, Luca, Pantano, Ilenia, Cavagna, Lorenzo, Conforti, Alessandro, Cauli, Alberto, Marucco, Elena Maria, Kucuk, Hamit, Ionescu, Ruxandra, Mattioli, Irene, Espinosa, Gerard, Araújo, Olga, Karkaş, Burak, Canofari, Claudia, Sota, Jurgen, Laymouna, Ahmed Hatem, Bedaiwi, Asma. A., Colella, Sergio, Giardini, Henrique Ayres M., Albano, Valeria, Lo Monaco, Andrea, Fragoulis, George E., Kardas, Riza Can, Berlengiero, Virginia, Hussein, Mohamed A., Ricci, Francesca, La Torre, Francesco, Rigante, Donato, Więsik-Szewczyk, Ewa, Frassi, Micol, Gentileschi, Stefano, Tosi, Gian Marco, Dagostin, Marilia Ambiel, Mahmoud, Ayman Abdel-Monem Ahmed, Tarsia, Maria, Alessio, Giovanni, Cimaz, Rolando, Giani, Teresa, Gaggiano, Carla, Iannone, Florenzo, Cipriani, Paola, Mourabi, Mariam, Spedicato, Veronica, Barneschi, Sara, Aragona, Emma, Balistreri, Alberto, Frediani, Bruno, Fabiani, Claudia, and Cantarini, Luca

Published
2022
Full Text
View/download PDF

3. Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries

Author

Vitale, Antonio, primary, Caggiano, Valeria, additional, Tufan, Abdurrahman, additional, Ragab, Gaafar, additional, Batu, Ezgi Deniz, additional, Portincasa, Piero, additional, Aragona, Emma, additional, Sota, Jurgen, additional, Conti, Giovanni, additional, De Paulis, Amato, additional, Rigante, Donato, additional, Olivieri, Alma Nunzia, additional, Şahin, Ali, additional, La Torre, Francesco, additional, Lopalco, Giuseppe, additional, Cattalini, Marco, additional, Maggio, Maria Cristina, additional, Insalaco, Antonella, additional, Sfikakis, Petros P., additional, Verrecchia, Elena, additional, Yildirim, Derya, additional, Kucuk, Hamit, additional, Kardas, Riza Can, additional, Laymouna, Ahmed Hatem, additional, Ghanema, Mahmoud, additional, Saad, Moustafa Ali, additional, Sener, Seher, additional, Ercan Emreol, Hulya, additional, Ozen, Seza, additional, Jaber, Nour, additional, Khalil, Mohamad, additional, Di Ciaula, Agostino, additional, Gaggiano, Carla, additional, Malizia, Giuseppe, additional, Affronti, Andrea, additional, Patroniti, Serena, additional, Romeo, Meri, additional, Sbalchiero, Jessica, additional, Della Casa, Francesca, additional, Mormile, Ilaria, additional, Silvaroli, Sara, additional, Gicchino, Maria Francesca, additional, Çelik, Neşe Çabuk, additional, Tarsia, Maria, additional, Karamanakos, Anastasios, additional, Hernández-Rodríguez, José, additional, Parronchi, Paola, additional, Opris-Belinski, Daniela, additional, Barone, Patrizia, additional, Recke, Andreas, additional, Costi, Stefania, additional, Sfriso, Paolo, additional, Giardini, Henrique A. Mayrink, additional, Gentileschi, Stefano, additional, Wiesik-Szewczyk, Ewa, additional, Vasi, Ibrahim, additional, Loconte, Roberta, additional, Jahnz-Różyk, Karina, additional, Martín-Nares, Eduardo, additional, Torres-Ruiz, Jiram, additional, Cauli, Alberto, additional, Conforti, Alessandro, additional, Emmi, Giacomo, additional, Li Gobbi, Francesca, additional, Biasi, Giovanni Rosario, additional, Terribili, Riccardo, additional, Ruscitti, Piero, additional, Del Giudice, Emanuela, additional, Tharwat, Samar, additional, Brucato, Antonio Luca, additional, Ogunjimi, Benson, additional, Hinojosa-Azaola, Andrea, additional, Balistreri, Alberto, additional, Fabiani, Claudia, additional, Frediani, Bruno, additional, and Cantarini, Luca, additional

Published
2024
Full Text
View/download PDF

4. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).

Author

Benucci, Maurizio, Bardelli, Marco, Cazzato, Massimiliano, Bartoli, Francesca, Damiani, Arianna, Li Gobbi, Francesca, Bandinelli, Francesca, Panaccione, Anna, Di Cato, Luca, Niccoli, Laura, Frediani, Bruno, Mosca, Marta, Guiducci, Serena, and Cantini, Fabrizio

Subjects
OLDER patients, AGE differences, MEDIAN (Mathematics), AGE groups, THROMBOEMBOLISM
Abstract

Background: According to recent data, the age of patients could represent an important risk factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) during treatment with JAK inhibitors in rheumatoid arthritis. We decided to analyze the population involved in the ReLiFiRa study by identifying two groups of patients: 65 years or more and less than 65 years of age, evaluating the efficacy and tolerability of 200 mg of Filgotinib daily. Methods: Of the 120 ReLiFiRa patients, 54 were younger than 65 years old and 66 patients were 65 years old or older. The data of efficacy and tolerability of treatment with FIL 200 mg daily for 6 months were evaluated. Results: After six months of treatment, FIL was effective in both age groups. In both groups, the median values of steroid DAS28, CDAI, ERS, PCR, tender joints, swollen joints, VAS, HAQ, PGA patients, and PGA physicians were reduced with a statistically significant difference comparing these values with the baseline values. The difference in age did not impact the effectiveness of the drug. The lipid profile data also did not demonstrate significant differences between the two age groups; however, the comparison between younger vs. older patients' populations regarding the total cholesterol/HDL ratio and LDL/HDL ratio shows a statistically significant difference: total cholesterol/HDL 3.4 (2.12–3.66) vs. 3.64 (3.36–4.13) p = 0.0004, LDL/HDL 1.9 (0.98–2.25) vs. 2.41 (2.04–2.73) p = 0.0002. There are no differences regarding the atherogenic index (LDL-C/HDL-C) and coronary risk index (TC/HDL-C) compared to baseline. Conclusions: After six months of treatment with FIL, the older population group showed a higher level of LDL and a lower level of HDL compared to younger patients. The atherogenic index and coronary risk index are higher in patients aged ≥ 65 years, but interestingly, there were no differences when comparing the 6-month data to baseline values. This condition highlights the impact of typical risk factors that act independently of treatment with Filgotinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study.

Author

Bandinelli, Francesca, Benucci, Maurizio, Mallia, Ilenia, Mauro, Ilaria, Pecani, Nikita, Li Gobbi, Francesca, Manfredi, Mariangela, Guiducci, Serena, Lari, Barbara, Grossi, Valentina, Infantino, Maria, and Giannasi, Gianfranco

Subjects
LUNGS, RHEUMATOID arthritis, BIOMARKERS, SMOKING, RHEUMATOID factor, ULTRASONIC imaging
Abstract

Background: Lung ultrasound (LUS) is a tool of growing interest in Rheumatoid Arthritis (RA) oligo- symptomatic ILD to avoid. Objective: We aimed to evaluate (i) the prevalence of pleural (PLUS) and parenchymal (PAUS) abnormalities in LUS in the RA population and their possible correlation to biomarkers; (ii) the predictivity of gender, smoking habits, previous infections (past COVID-19 tuberculosis), and treatments; (iii) the differences in LUS between sexes. Methods: We collected the data of 155 (15 early and 140 late) RA patients with mild respiratory symptoms, evaluating PLUS and PAUS, in fourteen lung areas and also summing the scores (LUS-T). Results: Only 13/155 (8.4%) were completely negative; LUS correlated to age (all parameters p 0.0001), rheumatoid factor IgM (PLUS p 0.0006, PAUS p 0.02, LUS-T p 0.001) and ACPA (p 0.001, 0.006, 0.001, respectively), and PLUS also correlated to IL6 (p 0.02). The male gender was predictive of all LUS evaluations (p 0.001, 0.05, 0.001, respectively), which were higher than in women (p 0.001, 0.01, 0.001, respectively). Other potential risk factors were independent, except biological treatments, which showed a low predictivity to PLUS (p < 0.05). Conclusions: We can conclude that LUS is a useful technique in RA low respiratory symptoms and correlates with age, the most important RA biomarkers, and male sex. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Author

Picchianti-Diamanti, Andrea, primary, Navarra, Assunta, additional, Aiello, Alessandra, additional, Laganà, Bruno, additional, Cuzzi, Gilda, additional, Salmi, Andrea, additional, Vanini, Valentina, additional, Maggi, Fabrizio, additional, Meschi, Silvia, additional, Matusali, Giulia, additional, Notari, Stefania, additional, Agrati, Chiara, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, Passarini, Damiano, additional, Di Gioia, Valeria, additional, Sesti, Giorgio, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Corpolongo, Angela, additional, Chimenti, Maria Sole, additional, Ferraioli, Mario, additional, Sebastiani, Gian Domenico, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Santoro, Anna Paola, additional, Capri, Andrea, additional, Puro, Vincenzo, additional, Nicastri, Emanuele, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

7. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA- i Study).

Author

Benucci, Maurizio, Li Gobbi, Francesca, Damiani, Arianna, Russo, Edda, Guiducci, Serena, Manfredi, Mariangela, Lari, Barbara, Grossi, Valentina, and Infantino, Maria

Subjects
*CALPROTECTIN, *RHEUMATOID arthritis, *MAJOR adverse cardiovascular events, *PLASMINOGEN activators, *HERPES zoster
Abstract

Background: Real-world evidence of the efficacy and adverse events of JAK inhibitor treatment (Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib) in rheumatoid arthritis is still limited. Methods: We studied 115 patients from the Rheumatology Unit of S. Giovanni di Dio Hospital affected by D2T-RA, according to the 2010 EULAR criteria. Out of the 115 patients, 17 had been treated with Baricitinib 8 mg/daily, 32 with Filgotinib 200 mg/daily, 21 with Tofacitinib 10 mg/daily, and 45 with Upadacitinib 15 mg/daily. We evaluated the clinical response after 3, 6, and 12 months of treatment and the follow-up from September 2022 to September 2023. All patients were evaluated according to the number of tender joints (NTJs), number of swollen joints (NSJs), visual analog scale (VAS), global assessment (GA), health assessment questionnaire (HAQ), Disease Activity Score (DAS28), and CDAI. Furthermore, laboratory parameters of efficacy and tolerability were evaluated. Results: All treatments demonstrated a statistically significant decrease in the DAS28 and CDAI scores, tender and swollen joint counts, VAS, HAQ, and patient global assessment (PGA) after 3, 6, and 12 months of treatment. All treatments showed similar behavior, and statistically significant decreases in circulating calprotectin, TNFα, and IL-6 were observed for all drugs after 12 months of treatment. In addition, soluble urokinase plasminogen activator receptor (suPAR) values showed significant differences at baseline and after 12 months of treatment for Filgotinib: 4.87 ± 4.53 vs. 3.61 ± 0.9 (0.009) and Upadacitinib: 6.64 ± 7.12 vs. 4.06 ± 3.61 (0.0003), while no statistically significant differences were found for Baricitinib: 3.4 ± 0.1 vs. 3.78 ± 0.1 and Tofacitinib: 3.95 ± 1.77 vs. 2.58 ± 0.1. The TC/HDL-C ratio (atherogenic index) showed significant differences when comparing Baricitinib vs. Filgotinib (0.0012), Filgotinib vs. Tofacitinib (0.0095), and Filgotinib vs. Upadacitinib (0.0001); furthermore, the LDL-C/HDL-C ratio in the Filgotinib group did not change (2.37 ± 0.45 vs. 2.35 ± 2.13 (NS)) after 12 months of treatment. Venous Thrombotic Events (VTEs) and major adverse cardiovascular events (MACEs) accounted for 1% of adverse events after treatment with Baricitinib. Herpes zoster reactivation accounted for 1% of adverse events after treatment with Filgotinib and Tofacitinib, while non-melanoma skin cancer (NMSC) accounted for 1% of adverse events after Upadacitinib treatment. Conclusions: Our real-world data from patients with RA show differences in some laboratory parameters and in the impact of lipid metabolism in JAK inhibitor treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Author

Benucci, Maurizio, primary, Bardelli, Marco, additional, Cazzato, Massimiliano, additional, Laurino, Elenia, additional, Bartoli, Francesca, additional, Damiani, Arianna, additional, Li Gobbi, Francesca, additional, Panaccione, Anna, additional, Di Cato, Luca, additional, Niccoli, Laura, additional, Frediani, Bruno, additional, Mosca, Marta, additional, Guiducci, Serena, additional, and Cantini, Fabrizio, additional

Published
2023
Full Text
View/download PDF

9. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project

Author

Gaggiano, Carla, primary, Del Bianco, Alessandra, additional, Sota, Jurgen, additional, Gentileschi, Stefano, additional, Ruscitti, Piero, additional, Giacomelli, Roberto, additional, Piga, Matteo, additional, Crisafulli, Francesca, additional, Monti, Sara, additional, Emmi, Giacomo, additional, De Paulis, Amato, additional, Vitale, Antonio, additional, Tarsia, Maria, additional, Caggiano, Valeria, additional, Nuzzolese, Rossana, additional, Parretti, Veronica, additional, Fabiani, Claudia, additional, Lopalco, Giuseppe, additional, Maier, Armin, additional, Cattalini, Marco, additional, Rigante, Donato, additional, Govoni, Marcello, additional, Li Gobbi, Francesca, additional, Guiducci, Serena, additional, Parronchi, Paola, additional, Marino, Achille, additional, Ciccia, Francesco, additional, Maggio, Maria Cristina, additional, Aragona, Emma, additional, Bartoloni, Elena, additional, Iagnocco, Annamaria, additional, Viapiana, Ombretta, additional, Sebastiani, Gian Domenico, additional, Guerriero, Silvana, additional, Insalaco, Antonella, additional, Del Giudice, Emanuela, additional, Conti, Giovanni, additional, Barone, Patrizia, additional, Olivieri, Alma Nunzia, additional, Brucato, Antonio, additional, Carubbi, Francesco, additional, Triggianese, Paola, additional, Mauro, Angela, additional, Tosi, Gian Marco, additional, Fonollosa, Alex, additional, Giardini, Henrique Ayres Mayrink, additional, Ragab, Gaafar, additional, Tharwat, Samar, additional, Hernández-Rodríguez, José, additional, Sfikakis, Petros P., additional, Laskari, Katerina, additional, Karamanakos, Anastasios, additional, Espinosa, Gerard, additional, Shahram, Farhad, additional, Direskeneli, Haner, additional, Hinojosa-Azaola, Andrea, additional, Opris-Belinski, Daniela, additional, AlMaghlouth, Ibrahim A., additional, Hatemi, Gülen, additional, Eksin, Mehmet Akif, additional, Önen, Fatos, additional, Więsik-Szewczyk, Ewa, additional, Akkoç, Nurullah, additional, Tufan, Abdurrahman, additional, Şahin, Ali, additional, Erten, Şükran, additional, Ozen, Seza, additional, Batu, Ezgi Deniz, additional, Frediani, Bruno, additional, Balistreri, Alberto, additional, and Cantarini, Luca, additional

Published
2023
Full Text
View/download PDF

10. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis

Author

Picchianti Diamanti, Andrea, primary, Navarra, Assunta, additional, Cuzzi, Gilda, additional, Aiello, Alessandra, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, De Lorenzo, Chiara, additional, Vio, Daniele, additional, Sebastiani, Giandomenico, additional, Ferraioli, Mario, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Cantini, Fabrizio, additional, Polidori, Vittoria, additional, Simmaco, Maurizio, additional, Cialdi, Esmeralda, additional, Scolieri, Palma, additional, Bruzzese, Vincenzo, additional, Nicastri, Emanuele, additional, D’Amelio, Raffaele, additional, Laganà, Bruno, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

11. Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2023
Full Text
View/download PDF

12. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Russo, Edda, additional, Guiducci, Serena, additional, Li Gobbi, Francesca, additional, Fusi, Paola, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Manfredi, Mariangela, additional, and Infantino, Maria, additional

Published
2022
Full Text
View/download PDF

13. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2022
Full Text
View/download PDF

14. Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome

Author

Vitale, Antonio, primary, Caggiano, Valeria, additional, Della Casa, Francesca, additional, Hernández-Rodríguez, José, additional, Frassi, Micol, additional, Monti, Sara, additional, Tufan, Abdurrahman, additional, Telesca, Salvatore, additional, Conticini, Edoardo, additional, Ragab, Gaafar, additional, Lopalco, Giuseppe, additional, Almaghlouth, Ibrahim, additional, Pereira, Rosa Maria R., additional, Yildirim, Derya, additional, Cattalini, Marco, additional, Marino, Achille, additional, Giani, Teresa, additional, La Torre, Francesco, additional, Ruscitti, Piero, additional, Aragona, Emma, additional, Wiesik-Szewczyk, Ewa, additional, Del Giudice, Emanuela, additional, Sfikakis, Petros P., additional, Govoni, Marcello, additional, Emmi, Giacomo, additional, Maggio, Maria Cristina, additional, Giacomelli, Roberto, additional, Ciccia, Francesco, additional, Conti, Giovanni, additional, Ait-Idir, Djouher, additional, Lomater, Claudia, additional, Sabato, Vito, additional, Piga, Matteo, additional, Sahin, Ali, additional, Opris-Belinski, Daniela, additional, Ionescu, Ruxandra, additional, Bartoloni, Elena, additional, Franceschini, Franco, additional, Parronchi, Paola, additional, de Paulis, Amato, additional, Espinosa, Gerard, additional, Maier, Armin, additional, Sebastiani, Gian Domenico, additional, Insalaco, Antonella, additional, Shahram, Farhad, additional, Sfriso, Paolo, additional, Minoia, Francesca, additional, Alessio, Maria, additional, Makowska, Joanna, additional, Hatemi, Gülen, additional, Akkoç, Nurullah, additional, Li Gobbi, Francesca, additional, Gidaro, Antonio, additional, Olivieri, Alma Nunzia, additional, Al-Mayouf, Sulaiman M., additional, Erten, Sükran, additional, Gentileschi, Stefano, additional, Vasi, Ibrahim, additional, Tarsia, Maria, additional, Mahmoud, Ayman Abdel-Monem Ahmed, additional, Frediani, Bruno, additional, Fares Alzahrani, Musa, additional, Laymouna, Ahmed Hatem, additional, Ricci, Francesca, additional, Cardinale, Fabio, additional, Jahnz-Rózyk, Karina, additional, Tosi, Gian Marco, additional, Crisafulli, Francesca, additional, Balistreri, Alberto, additional, Dagostin, Marília A., additional, Ghanema, Mahmoud, additional, Gaggiano, Carla, additional, Sota, Jurgen, additional, Di Cola, Ilenia, additional, Fabiani, Claudia, additional, Giardini, Henrique A. Mayrink, additional, Renieri, Alessandra, additional, Fabbiani, Alessandra, additional, Carrer, Anna, additional, Bocchia, Monica, additional, Caroni, Federico, additional, Rigante, Donato, additional, and Cantarini, Luca, additional

Published
2022
Full Text
View/download PDF

15. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Infantino, Maria, additional, Manfredi, Mariangela, additional, Lari, Barbara, additional, Grossi, Valentina, additional, Mariotti, Elena Biancamaria, additional, Corrà, Alberto, additional, Aimo, Cristina, additional, Quintarelli, Lavinia, additional, Verdelli, Alice, additional, Li Gobbi, Francesca, additional, Antiga, Emiliano, additional, and Caproni, Marzia, additional

Published
2022
Full Text
View/download PDF

16. Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data

Author

Benucci, Maurizio, Damiani, Arianna, Li Gobbi, Francesca, Grossi, Valentina, Infantino, Maria, Manfredi, Mariangela, Niccoli, Laura, and Cantini, Fabrizio

Subjects
ixekizumab, ankylosing spondylitis, randomized control trials, Review
Abstract

Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. For more than 10 years, anti-TNF biologics were successfully employed to treat AS, with marked improvement of signs and symptoms in around 60% of the patients. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis. New therapies with selective biological drugs have emerged in the treatment of this pathology. In this review, we evaluated the effects of ixekizumab, a new anti–IL-17A, that was licensed both by EMA and FDA in August 2019 for the treatment of ankylosing spondylitis. The review highlights the efficacy and safety data of the 3 randomized controlled trials (COAST V-COAST W-COAST X) and those of the extension to 52 weeks of COAST V and COAST W.

Published
2020

20. Do new and old biomarkers of early undifferentiated arthritis correlate with Arthritis Impact Measurement Scales?

Author

Bandinelli, Francesca, primary, Benucci, Maurizio, additional, Salaffi, Fausto, additional, Manetti, Mirko, additional, Infantino, Maria, additional, Damiani, Arianna, additional, Manfredi, Mariangela, additional, Grossi, Valentina, additional, Matucci, Alessandra, additional, Li Gobbi, Francesca, additional, and Marin, Gabriella, additional

Published
2021
Full Text
View/download PDF

24. Vantaggi, limiti e prospettive dei test sierologici nell'infezione da SARS-CoV-2 (COVID-19)

Author

Infantino, Maria, primary, Damiani, Arianna, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Lari, Barbara, additional, Macchia, Donatella, additional, Casprini, Patrizia, additional, Veneziani, Francesca, additional, Villalta, Danilo, additional, Bizzaro, Nicola, additional, Cappelletti, Piero, additional, Fabris, Martina, additional, Quartuccio, Luca, additional, Benucci, Maurizio, additional, and Manfredi, Mariangela, additional

Published
2020
Full Text
View/download PDF

28. Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life

Author

Benucci,Maurizio, Damiani,Arianna, Manfredi,Mariangela, Infantino,Maria, Grossi,Valentina, and Li Gobbi,Francesca

Subjects
musculoskeletal diseases, ClinicoEconomics and Outcomes Research
Abstract

Maurizio Benucci,1 Arianna Damiani,1 Mariangela Manfredi,2 Maria Infantino,2 Valentina Grossi,2 Francesca Li Gobbi11Rheumatology Unit, S.Giovanni di Dio Hospital, Florence, Italy; 2Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerable impact on lowering the direct medical costs of RA in Italy. Abatacept, a selective T-cell costimulation modulator, is a valuable treatment option for patients with moderate-to-severe RA. A search using the keywords “cost-effectiveness analysis", "budget impact model", "abatacept", and "rheumatoid arthritis” was carried out on PubMed. Abatacept in the first- and second-treatment lines has been evaluated in our research. We evaluated patients with inadequate MTX response, inadequate anti-TNF agents response, switch studies and real-world data. Furthermore, in our research, we evaluated the main head-to-head studies published.Keywords: abatacept, budget impact model, cost-effectiveness analysis, rheumatoid arthritis

Published
2019

29. Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

Author

Niccoli,Laura, Nannini,Carlotta, Blandizzi,Corrado, Mantarro,Stefania, Mosca,Marta, Di Munno,Ombretta, Goletti,Delia, Benucci,Maurizio, Li Gobbi,Francesca, Cassarà ,Emanuele, Kaloudi,Olga, and Cantini,Fabrizio

Subjects
Therapeutics and Clinical Risk Management
Abstract

Laura Niccoli,1 Carlotta Nannini,1 Corrado Blandizzi,2 Stefania Mantarro,2 Marta Mosca,3 OmbrettaDi Munno,3 Delia Goletti,4 Maurizio Benucci,5 FrancescaLi Gobbi,5 Emanuele Cassarà,1 Olga Kaloudi,1 Fabrizio Cantini1 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Section of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 3Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 4Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases, Rome, Italy; 5Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Objective: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD). Methods: An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated. Results: ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients. Conclusion: The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes. Keywords: biologics, immunogenicity, infections, lupus-like syndrome, osteoporosis, periodontal disease, sexuality

Published
2018

31. Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2–Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays

Author

Grossi, Valentina, primary, Infantino, Maria, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Bandinelli, Francesca, additional, Damiani, Arianna, additional, Bodio, Caterina, additional, Borghi, Maria Orietta, additional, Mahler, Michael, additional, Aure, Mary Ann, additional, Bentow, Chelsea, additional, and Manfredi, Mariangela, additional

Published
2019
Full Text
View/download PDF

32. Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience

Author

Infantino, Maria, primary, Pregnolato, Francesca, additional, Bentow, Chelsea, additional, Mahler, Michael, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Damiani, Arianna, additional, Grossi, Valentina, additional, Franceschini, Franco, additional, Bodio, Caterina, additional, Borghi, Maria Orietta, additional, and Manfredi, Mariangela, additional

Published
2019
Full Text
View/download PDF

33. The Laboratory Role in anti-TNF Biological Therapy Era

Author

Grossi, Valentina, primary, Gulli, Francesca, additional, Infantino, Maria, additional, Stefanile, Annunziata, additional, Napodano, Cecilia, additional, Benucci, Maurizio, additional, Pocino, Krizia, additional, Li Gobbi, Francesca, additional, Damiani, Arianna, additional, Di Pino, Antonella, additional, Manfredi, Mariangela, additional, Marino, Mariapaola, additional, Basile, Valerio, additional, Rapaccini, Gian Ludovico, additional, and Basile, Umberto, additional

Published
2019
Full Text
View/download PDF

34. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports.

Author

Grossi, Valentina, Infantino, Maria, Manfredi, Mariangela, Basile, Umberto, Gulli, Francesca, Marino, Mariapaola, Li Gobbi, Francesca, Damiani, Arianna, Atzeni, Fabiola, and Benucci, Maurizio

Subjects
TUMOR necrosis factors, SARCOIDOSIS, ANTIBODY titer, LEUKOCYTE count
Abstract

It has been shown that in patients with rheumatoid arthritis, switched to a second anti-TNF drug for the development of ADAs against the starting agent, the clinical outcome may significantly ameliorate, even better than in patients not developing ADAs [7]. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. [Extracted from the article]

Published
2020
Full Text
View/download PDF

36. The Laboratory Role in anti-TNF Biological Therapy Era.

Author

Grossi, Valentina, Gulli, Francesca, Infantino, Maria, Stefanile, Annunziata, Napodano, Cecilia, Benucci, Maurizio, Pocino, Krizia, Li Gobbi, Francesca, Damiani, Arianna, Di Pino, Antonella, Manfredi, Mariangela, Marino, Mariapaola, Basile, Valerio, Rapaccini, Gian Ludovico, and Basile, Umberto

Subjects
BIOTHERAPY, DISEASES, RHEUMATISM, INDIVIDUALIZED medicine, THERAPEUTICS
Abstract

Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient's group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

37. Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2–Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays.

Author

Grossi, Valentina, Infantino, Maria, Benucci, Maurizio, Li Gobbi, Francesca, Bandinelli, Francesca, Damiani, Arianna, Bodio, Caterina, Borghi, Maria Orietta, Mahler, Michael, Aure, Mary Ann, Bentow, Chelsea, and Manfredi, Mariangela

Subjects
IMMUNOASSAY, ANTIPHOSPHOLIPID syndrome, SJOGREN'S syndrome, IMMUNOGLOBULINS, IMMUNOLOGIC diseases, PREGNANCY complications
Abstract

In the present study, we evaluated two novel technologies, the chemiluminescent immunoassay (CIA) QUANTA Flash on BIO-FLASH (Inova Diagnostics, San Diego, CA, USA) and the addressable laser bead immunoassay (ALBIA) on BioPlex™ 2200 (Bio-Rad, Hercules, CA, USA) for the detection of anti-cardiolipin IgG/IgM (aCL) and anti-β2–glycoprotein IgG/IgM (aβ2GPI) antibodies. The study was performed on 134 samples from consecutive patients (59 males and 75 females, mean age 54 ± 10 years) who consulted a rheumatologist because thrombosis and/or pregnancy complications were present or another immunological disease (Sjogren's syndrome, inflammatory arthritis). Fourteen patients of the total fulfilled 25the Sydney criteria for APS and for these patients previous results of aPLs were available. Sera were tested for aCL and aβ2GPI of IgG and IgM isotypes using CIA (BIO-FLASH) and ALBIA (BioPlex™ 2200). Overall agreement between CIA and ALBIA ranged from 88.1% (aCL IgG) to 97.8% (aβ2GPI IgG). Cohen's kappa coefficient ranged from 0.53 to 0.91, implying moderate to almost perfect agreement. Almost perfect agreement was found between BioPlex™ 2200 and BIO-FLASH aβ2GPI IgG and aCL IgM with Cohen's kappa of 0.91 and 0.88, respectively. On the other hand, moderate agreement was found between BioPlex™ 2200 and BIO-FLASH aCL IgG and β2GPI IgM assays with Cohen's kappa of 0.57 and 0.53, respectively. The two novel technologies look promising and comparable but further studies with larger cohorts are needed to contribute to the better understanding of the new aPLs antibodies assays performance. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers

Author

Grossi, Valentina, Infantino, Maria, Meacci, Francesca, Bellio, Emanuele, Bellio, Valerio, Ciotta, Giovanna, Priami, Fiorella, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola, Li Gobbi, Francesca, Damiani, Arianna, Benucci, Maurizio, and Manfredi, Mariangela

Subjects
Histology, Humans, Absolute count, AQUIOS, Flow cytometry, Percentage count, 2734, Cell Biology, Lymphocyte Count, Flow Cytometry, Laboratories, Immunophenotyping, Workflow
Abstract

Measurement of lymphocyte subpopulations is a crucial parameter in the diagnosis and monitoring of therapy in a wide variety of clinical conditions. We compared different flow cytometry-based methods to determine lymphocyte subsets counts of routine samples by volumetric AQUIOS CL (Beckman Coulter) and bead-based FACS CANTO II (BD Biosciences) cytometers. We evaluated the possible decrease of the labor intensive technical work using the fully automated AQUIOS CL system in the pre and post analytical steps in comparison with our routine flow cytometer FACS CANTO II, toward the reduction of laboratory analytical turnaround time (TAT).The analytical performance of AQUIOS CL flow cytometer compared with FACS CANTO II was evaluated testing 224 routine samples, attending the Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, (Florence, Italy) between September and October 2015.Bland-Altman plot of the differences between the two methods showed an excellent agreement for absolute and percentage counts. Furthermore, the study showed that automated AQUIOS CL system is simple to be used during all analytical steps with a reduction of TAT.In routine conditions, AQUIOS CL flow cytometer could be a suitable tool for subpopulations subset analysis. © 2017 International Clinical Cytometry Society.

Published
2016

41. Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers

Author

Grossi, Valentina, primary, Infantino, Maria, additional, Meacci, Francesca, additional, Bellio, Emanuele, additional, Bellio, Valerio, additional, Ciotta, Giovanna, additional, Priami, Fiorella, additional, Sarzi-Puttini, Piercarlo, additional, Atzeni, Fabiola, additional, Li Gobbi, Francesca, additional, Damiani, Arianna, additional, Benucci, Maurizio, additional, and Manfredi, Mariangela, additional

Published
2017
Full Text
View/download PDF

42. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Author

Cantini, Fabrizio, primary, Niccoli, Laura, additional, Nannini, Carlotta, additional, Cassarà, Emanuele, additional, Kaloudi, Olga, additional, Giulio Favalli, Ennio, additional, Becciolini, Andrea, additional, Biggioggero, Martina, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Infantino, Maria, additional, Meacci, Francesca, additional, Manfredi, Mariangela, additional, Guiducci, Serena, additional, Bellando-Randone, Silvia, additional, Matucci-Cerinic, Marco, additional, Foti, Rosario, additional, Di Gangi, Marcella, additional, Mosca, Marta, additional, Tani, Chiara, additional, Palmieri, Fabrizio, additional, and Goletti, Delia, additional

Published
2016
Full Text
View/download PDF

43. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab

Author

Benucci, Maurizio, primary, Meacci, Francesca, additional, Grossi, Valentina, additional, Infantino, Maria, additional, Manfredi, Mariangela, additional, Bellio, Emanuele, additional, Bellio, Valerio, additional, Li Gobbi, Francesca, additional, Bazzichi, Laura, additional, Moscato Paolo, Paolo, additional, Caputo, Dario, additional, Saviola, Gianantonio, additional, Talotta, Rossella, additional, Sarzi Puttini, Piercarlo, additional, and Atzeni, Fabiola, additional

Published
2016
Full Text
View/download PDF

47. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins

Author

Benucci, Maurizio, primary, Li Gobbi, Francesca, additional, Meacci, Francesca, additional, Manfredi, Mariangela, additional, Infantino, Maria, additional, Severino, Maurizio, additional, Atzeni, Fabiola, additional, Testi, Sergio, additional, Sarzi-Puttini, Piercarlo, additional, and Ricci, Cristian, additional

Published
2015
Full Text
View/download PDF

48. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment

Author

Bartalesi, Filippo, primary, Goletti, Delia, additional, Spinicci, Michele, additional, Cavallo, Annalisa, additional, Attala, Letizia, additional, Mencarini, Jessica, additional, Fiori, Ginevra, additional, Li Gobbi, Francesca, additional, Mantella, Antonia, additional, Benucci, Maurizio, additional, Prignano, Francesca, additional, Pimpinelli, Nicola, additional, Matucci Cerinic, Marco, additional, Girardi, Enrico, additional, and Bartoloni, Alessandro, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results